Phage-Derived Enzyme Therapeutics for Targeted Disruption of Healthcare-Associated Pathogens

Abstract

Healthcare-associated infections (HAIs) present a persistent challenge in clinical settings, with rising multidrug-resistant organisms heightening the urgency for novel antimicrobial strategies. Phage-derived enzymes, including endolysins and depolymerases, are emerging as precision therapeutics capable of targeting and disrupting pathogenic bacteria with remarkable specificity. This review evaluates the epidemiology of HAIs, the role of phage enzymes in disease pathophysiology, risk factors for infection, diagnostic approaches, and current evidence supporting the clinical implementation of these biologics. Key advances, practical clinical implications, and guideline considerations for integrating phage enzyme therapeutics are analyzed to inform effective management of HAIs in contemporary healthcare environments.

Introduction

Healthcare-associated pathogens are a leading cause of morbidity and mortality across the globe, exacerbated by the rise of antibiotic-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and carbapenem-resistant Enterobacterales (CRE). Traditional antimicrobials often fail due to resistance mechanisms, prompting the exploration of innovative approaches like phage-derived enzymes. These agents, harnessed from bacteriophages, possess potent, targeted bacteriolytic activity and offer promise as adjuncts or alternatives to conventional therapies. This review synthesizes current evidence and clinical perspectives on the application of phage-derived enzyme therapeutics against HAIs.

Epidemiology / Disease Burden

HAIs affect millions of patients annually, accounting for substantial healthcare costs, prolonged hospitalizations, and increased mortality rates. According to the CDC, approximately 1 in 31 hospitalized patients in the United States acquires at least one HAI. The global burden is further amplified in resource-limited settings, where infection control practices may be suboptimal. Common pathogens include MRSA, VRE, multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii. The emergence of resistance to last-line agents, including colistin and carbapenems, underscores the critical need for alternative therapeutic strategies.

Pathophysiology

Phage-derived enzymes act by exploiting bacteriophage mechanisms for bacterial cell lysis. Endolysins, for example, hydrolyze peptidoglycan in Gram-positive bacteria, leading to rapid cell wall breakdown and bacterial death. Depolymerases target extracellular polysaccharides, disrupting biofilms and bacterial capsules, which are key virulence factors in HAI pathogens. Unlike broad-spectrum antibiotics, phage enzymes exhibit high specificity for target organisms, minimizing collateral damage to the commensal microbiota and reducing selective pressures that drive resistance development.

Risk Factors

Risk factors for HAIs include prolonged hospitalization, invasive procedures (e.g., mechanical ventilation, catheterization), immunosuppression, advanced age, prior antibiotic exposure, and intensive care unit admission. The presence of indwelling medical devices facilitates biofilm formation, serving as reservoirs for persistent infections and complicating eradication efforts with standard antibiotics.

Clinical Features

Patients with HAIs may present with a spectrum of manifestations, ranging from localized wound or device-related infections to life-threatening sepsis. Clinical features depend on the pathogen and infection site but often include fever, leukocytosis, signs of systemic inflammation, and organ dysfunction in severe cases. Biofilm-associated infections tend to be indolent, recurrent, and refractory to standard treatment, necessitating advanced therapeutic interventions.

Diagnosis

Accurate diagnosis of HAIs relies on a combination of clinical assessment, microbiological culture, molecular diagnostics (such as PCR for resistance genes), and imaging as appropriate. Rapid identification of the causative organism and its antimicrobial susceptibility profile is crucial for guiding targeted therapy. Emerging techniques, including high-throughput sequencing and mass spectrometry, are enhancing the speed and precision of pathogen detection in clinical microbiology laboratories.

Treatment & Management

Traditional management of HAIs centers on empiric and targeted antibiotic therapy, source control (e.g., device removal), and supportive care. However, escalating antibiotic resistance is compromising the efficacy of these interventions. Phage-derived enzymes offer a new modality for pathogen-specific lysis, with several agents in preclinical and clinical development. Endolysins, administered topically or systemically, demonstrate potent activity against Gram-positive pathogens, including MRSA and VRE. Depolymerases have shown efficacy in disrupting biofilms and capsules of Gram-negative bacteria, facilitating immune clearance and enhancing antibiotic penetration.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in the engineering and application of recombinant phage enzymes. Clinical trials have reported safety and efficacy of topical endolysins (such as CF-301/exebacase) in treating S. aureus bacteremia and endocarditis. Advances in protein engineering have broadened the activity spectrum of endolysins to include Gram-negative pathogens, previously shielded by the outer membrane. Combination therapies involving phage enzymes and antibiotics have demonstrated synergistic effects, reducing bacterial load and preventing resistance emergence. Additionally, encapsulation and targeted delivery systems are being developed to optimize pharmacokinetics and minimize immunogenicity.

Guideline Recommendations

While established guidelines (e.g., IDSA, ESCMID) continue to prioritize infection prevention and optimal antibiotic stewardship, leading expert panels now recognize the potential of phage-derived enzymes as adjunctive agents in refractory or multidrug-resistant infections. Protocols for compassionate use and clinical trial enrollment are evolving, with an emphasis on rigorous safety monitoring and standardized outcome measures. Integration of phage enzymes into clinical practice awaits further large-scale randomized controlled trial data, but current evidence supports their consideration in select, high-risk patient populations.

Conclusion

Phage-derived enzyme therapeutics represent a promising frontier in the targeted management of healthcare-associated pathogens, offering mechanistic specificity and a favorable safety profile compared to conventional antibiotics. Ongoing research and clinical trials will clarify their role in the evolving landscape of antimicrobial therapy, with the potential to transform the care of patients with resistant and recalcitrant HAIs. Close collaboration between microbiologists, infectious disease specialists, and regulatory authorities is essential to advance the translation of these biologics from bench to bedside, ultimately enhancing patient outcomes and public health.